Drug Trial Radar · NCT04659239
The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
Last checked: Nov 20, 2026Latest source record: Feb 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
34,020
Planned (sponsor's estimate)
Start
Jan 28, 2021
Primary completion
Sep 2021
Study completion Jul 2022
Sponsor
- Lead sponsor
- Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo controlled phase III clinical trial to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after 2-dose schedule.
Conditions
- COVID-19
Interventions
Inactivated SARS-CoV-2 Vaccine (Vero cell)Biological
The inactivated SARS-CoV-2 vaccine (vero cell) was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
PlaceboBiological
The placebo was manufactured by IMBCAMS. Each dose of 0.5ml is for per person per time use.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of COVID-19 cases after two-doses of vaccinationTime frame: From 14 days after the second dose to 1 year after the second dose.
- The incidence of solicited AEs.Time frame: 7 days after each dose
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
CEMEC Pesquisa Clinica
São Bernardo do Campo, São Paulo, Brazil
Hospital Sungai Buloh
Sungai Buloh, Selangor, Malaysia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.